Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer

Data presented at AACR Annual Meeting 2019

  • In vivo study conducted alone or in collaboration with The University of Texas MD Anderson Cancer Center demonstrated:
    • NBTXR3 in combination with a PD-1 inhibitor enhanced an abscopal effect in both sensitive and PD-1-inhibitor-resistant lung cancer models
    • NBTXR3
Read More

Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer

Data presented at AACR Annual Meeting 2019

  • In vivo study conducted alone or in collaboration with The University of Texas MD Anderson Cancer Center demonstrated:
    • NBTXR3 in combination with a PD-1 inhibitor enhanced an abscopal effect in both sensitive and PD-1-inhibitor-resistant lung cancer models
    • NBTXR3
Read More

Chaineum acts as STO Advisor for Carthagea

Chaineum, a France-based corporate finance advisory firm and a pioneering Initial Coin Offering (“ICO”) advisor, accompanies the first French law governed “Security Token Offering” (“STO”) on behalf of its client Carthagea.

A STO is a new fundraising trend consisting in the issuance of financial securities

Read More